Myeloproliferative neoplasms (MPNs) 
T he most common BCR-ABL1-negative MPNs (also referred to as the classical MPNs) are essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). The severity of these MPNs can range from mild to aggressive, and can severely affect patient quality of life (QOL) due to debilitating symptoms and an increased risk of thrombotic events. Since patients with these disorders can live for many years and often require long-term treatment and follow-up, nurses require a good understanding of the common BCR-ABL1-negative MPNs, their associated symptoms and how to help patients manage these symptoms. This article -the second of a two-part series -was developed by a group of Canadian nurse practitioners and specialized hematology/oncology nurses to provide nurses and other healthcare professionals with practical guidance for managing the symptom burden associated with the most common BCR-ABL1-negative MPNs. The first article in this series (also available in this issue) provides a review of the diagnosis and treatment of these disorders.
WHAt is tHe Nurse's rOle iN MANAGiNG tHe sYMPtOMs OF PAtieNts WitH MPNs?
MPNs are long-term chronic illnesses and the symptom burden associated with these disorders can be severe. The recent MPN Landmark survey, which was conducted from May to July 2014 and included 813 patients with MPNs (MF, n = 207; PV, n = 380; ET, n = 226) in the United States, was designed to assess the disease burden associated with MPNs . The survey found that these patients experience a broad symptom burden that leads to reductions in QOL, functional status, activities of daily living, and work productivity. Nurses play a key role in recognizing these symptoms and educating patients on self-management strategies, as well as identifying patients with unmet needs who may benefit from treatment modifications.
The MPN-10, formerly known as the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), is a validated instrument designed to quantitatively assess the burden of symptoms in patients with MPNs (see Figure 1) (Emanuel et al., 2012) . It can also be used to track disease progression and response to treatment, thereby facilitating disease management and enhancing the communication between nurses and patients.
The MPN-10 is available in paper form or as a web app (http://www.mpn10app.com/) and includes the 10 most clinically relevant symptoms of MPNs. Each symptom is scored from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be), with higher scores indicating a higher symptom burden. Repeating the MPN-10 assessment at subsequent visits can help provide a chronologic impression of symptom burden over time and determine the effects of treatment interventions, as well as symptom-management strategies.
WHY DO tHese cOMMON sYMPtOMs Occur AND WHAt strAteGies cAN Be useD tO HelP PAtieNts WitH tHese clAssicAl MPNs MANAGe tHese sYMPtOMs?
Regardless of the type of MPN, fatigue (which often leads to inactivity) is the most commonly reported disease-related symptom, occurring in 80-95% of patients with MPNs (Scherber et al., 2011) . It can be one of the most debilitating MPN symptoms, affecting not only physical and social functioning, but also substantially impairing QoL (Mesa et al., 2007) . In fact, it is one of the main reasons for the inability of patients with MPNs to work (i.e., 31% of patients with ET, 40% of patients with PV, and 59% of patients with MF are unable to work due to fatigue) (Michiels, 2016) .
Figure 1. The MPN-10
Fatigue is multifactorial in nature, resulting from: the release of pro-inflammatory cytokines (particularly interleukin [IL]-1, IL-6, IL-8, and tumour necrosis factor [TNF]-α); impaired hematopoiesis causing anemia, infection, thrombosis and microvascular symptoms; deconditioning; depression; and even medication side effects (Radia & Geyer, 2015; Scherber et al., 2016) . Given the multifactorial nature of this symptom, fatigue is often difficult to assess and treat. Management generally requires a multifaceted approach that includes treatment of the particular MPN, treatment of any underlying contributing factors (such as antibiotics for infection, red blood cell transfusions for anemia, platelet transfusions for low platelet counts, and antidepressant therapy for depression) and advising patients on various non-pharmacological approaches. The latter may include: encouraging patients to engage in regular physical activity; advising on sleep optimization and stress reduction strategies; monitoring fatigue patterns and planning activities according to peak energy periods; and referral to rehabilitation programs (Howell et al., 2015) . A recent survey of more than 1,700 MPN patients found that many non-pharmacological strategies were used to reduce fatigue (Scherber et al., 2016) . Participants reported that the most helpful strategies included: scheduling activities during times of peak energy, pacing activities, setting priorities, labour-saving devices, and walking. One of the most striking findings of this study was the strong correlation between exercise and reduced fatigue; subjects who were physically active reported less fatigue compared with those who were sedentary.
When used as indicated for the treatment of MPNs, ruxolitinib has been shown to reduce fatigue symptoms by approximately 50% compared to standard therapy (standard therapy was selected by the investigators and could include hydroxyurea, interferon, pipobroman, anagrelide, immunomodulators, or no medication) (Vannucchi et al., 2015) . Ruxolitinib has also been shown to reduce spleen size (which may improve activity levels) and to improve appetite (which may indirectly improve fatigue and inactivity by increasing energy levels) (Mesa et al., 2013; Verstovesk et al., 2012) .
Abdominal-related complaints in patients with MPNs, such as early satiety and abdominal discomfort/pain, are largely attributable to splenomegaly (Radia & Geyer HL, 2015) . The development of splenomegaly in MPNs is believed to result from splenic sequestration of blood cells and extramedullary hematopoiesis (Mughal et al., 2014) . The splenic enlargement prevents stomach expansion when eating and, hence, patients cannot eat large volumes, resulting in early satiety. In general, abdominal discomfort is due to the mechanical pressure of the spleen, but it can also result from splenic infarction causing pain that often requires analgesia.
The key goal for the management of early satiety is to maximize nutritional intake with minimal volume. Therefore, patients should be advised to consume small, frequent, high-energy, high-protein meals and snacks, as well as energy-dense liquids between meals to help meet fluid requirements (BC Cancer Agency, 2005) .
Patients experiencing abdominal discomfort should be instructed to take medications that have been shown to reduce spleen size (e.g., hydroxyurea and ruxolitinib-discussed in Part 1 of this two-part series), as prescribed (Cervantes, 2011; Harrison et al., 2012 Harrison et al., , 2016 . Splenectomy (surgical removal of the spleen) may also be beneficial for relieving abdominal pain. However, given the risks associated with this procedure, it is usually reserved for patients who are refractory to drug treatment, or who have transfusion-dependent anemia that is unresponsive to therapy, or portal hypertension (Cervantes, 2011) . Splenic radiation is also an option for poor surgical candidates and for palliation of severe pain from splenic infarcts. However, the effects of radiation may not be durable.
Pruritus, described as generalized itching, prickling, or burning, tends to be more common in patients with PV than other MPNs . It is usually triggered by exposure to water of any temperature (aquagenic pruritus), but may also be triggered by other stimuli such as a sudden change in temperature, sitting next to a fire, sweating after exercise, alcohol consumption, or the use of warm bedclothes at night (Saini et al., 2010; Radia & Geyer, 2015) . It can also develop spontaneously, without recognizable precipitating factors, or be constantly present. Although the pathophysiology of pruritus in patients with MPNs is not completely understood, it is believed to be related to the release of pro-inflammatory cytokines. The management of PV-associated pruritus is largely based on empirical evidence, and may include interferon-alpha, selective serotonin reuptake inhibitors (SSRIs), antihistamines, avoidance of triggers, use of emollients, and narrow band ultraviolet B (UVB) phototherapy for severe cases (Saini et al., 2010; Radia & Geyer, 2015) .
Bone pain can be a presenting or late feature of MF. Although the pathophysiology of bone pain in MF is not completely understood, it is believed to be due to overproliferation of the bone marrow, periostitis (inflammation of periosteum, which is the layer of connective tissue surrounding bone) and osteosclerosis (hardening of the bone) associated with MF (Neben-Wittich et al., 2010) . Opioids are commonly used for bone pain in MF, but some patients may not experience relief from these medications. Case reports have shown low-dose radiation to be effective in patients unresponsive to pain medications (Neben-Wittich et al., 2010) .
Problems with concentration are typically microvascular symptoms that result from disease activity occurring at a capillary level. They also appear to be related to the production of pro-inflammatory cytokines that disrupt neurohormonal signalling and impair neurotransmitter production . Other common MPN-associated symptoms, such as fever, night sweats and weight loss, are also related to the release of pro-inflammatory cytokines during the disease process Hermouet et al., 2015) . Treatment with ruxolitinib has been shown to improve these constitutional symptoms compared to standard therapy or placebo (Vannucchi et al., 2015; Mesa et al., 2013; Verstovesk et al., 2012) . For patients with concentration problems, relaxation, meditation, memory aids and mind-stimulating activities can be helpful (Centers for Disease Control and Prevention, 2013). For patients experiencing weight loss, referral to a dietician for nutritional counselling may be required. Table 1 provides practical non-pharmacological strategies for the management of the common MPN-associated symptoms. Table 2 lists both nursing and patient resources that may be helpful for managing the symptoms of MPNs. • establish a regular bedtime routine • avoid naps during the day • control noise, light and temperature at bedtime • avoid caffeine and alcohol before bed • Instruct patients to monitor fatigue patterns and plan activities according to peak energy periods • Advise on stress reduction strategies (e.g., yoga and mindfulness programs) • Advise on attention-restoring therapies that may distract from fatigue:
• reading, games, music, gardening, experiencing nature • Refer to rehabilitation or psychosocial/educational programs that provide guidance about fatigue patterns, energy balancing and coping skills training, and coaching in fatigue self-management
Concentration problems
• Advise patients on the use of memory aids (e.g., organizers, schedulers, written resource manuals) • Provide and/or refer for relaxation/meditation training • Encourage patients to engage in activities that stimulate the mind (e.g., puzzles, word games, card games)
Early satiety • Advise patients to consume small, frequent, high-energy, high-protein meals and snacks, as well as energy-dense liquids between meals to help meet fluid requirements • Instruct patients to avoid high-fibre or common gas-producing foods that may contribute to satiety • Advise patients to chew food well and to eat meals slowly, in a relaxed environment • Encourage patients to drink fluids 30 minutes before or after meals/snacks
Inactivity
• See section on fatigue Night sweats • Note: since this is a constitutional/cytokine-related symptom, only pharmacological treatment will be beneficial. Consider instructing patients to monitor the frequency and severity of night sweats, as this may help determine when MPN treatment should be initiated
Itching
• Emollients • Avoidance of triggers:
• very hot baths/showers • caffeine, alcohol, chocolate and sugar • Narrow band UVB phototherapy for severe cases Bone pain
• Note: since this is a cytokine-related symptom, only pharmacological treatment will be beneficial. Consider instructing patients to report whether opioid pain medication use has increased or has become ineffective for managing bone pain. In these cases, MPN treatment or referral to a pain management team for supportive care may be required
Abdominal discomfort
• Instruct patients to avoid:
• tight-fitting clothing around the abdominal area • contact sports that may predispose to blunt abdominal trauma
Surgical:
• Splenectomy*
Other:
• Splenic radiation* (for poor surgical candidates and for palliation of severe pain from splenic infarcts)
Weight loss • Referral to a dietitian for nutrition counselling • See section on early satiety Fever • Note: since this is a cytokine-related symptom, only pharmacological treatment will be beneficial. Consider instructing patients to report the frequency of fever and its impact on QoL, as this may help determine when MPN treatment should be initiated. Also, discuss and document signs of infection with patient so that physician can rule out infection as the cause of fever *Should only be considered on an individual case-by-case basis. These procedures do not improve disease outcomes, but only relieve symptoms associated with an enlarged spleen. Both options carry a high risk of side effects, and patients should further discuss these procedures in detail with their healthcare provider.
Although this article focuses on managing the unique physical symptoms of patients with MPNs, the authors recognize that nurses may also play an important role in addressing the psychosocial needs of patients with these disorders, which are similar to those of patients with other forms of cancer. A detailed review of the psychosocial impact of cancer and how nurses can support the emotional, social and psychological needs of patients with malignancies is beyond the scope of this review. However, the authors have included helpful psychosocial resources, such as the Canadian Association of Psychosocial Oncology (CAPO) website, in Table 1 (see "Other Resources for Nurses and Patients" section).
cONclusiONs
The symptom burden experienced by patients with the classical MPNs can be significant and can negatively impact QOL, activities of daily living, and the ability to work and be productive, even in patients with low prognostic risk scores and a low symptom burden. Improvements in symptom recognition and implementing strategies to help patients with MPNs manage these symptoms can ameliorate these negative effects and, thereby, help enhance the overall health and lives of patients with MPNs. As a primary patient contact, nurses play an essential role in communicating with patients with MPNs, assessing their symptoms and educating them on treatments and strategies that can reduce their symptom burden. Ideally, all patients with MPNs should be managed in a shared-care model, with close collaboration between nurses, a community hematologist/oncologist and a tertiary-care centre with expertise in MPNs.
In addition, nurses could play an important role in conducting future research on the use of non-pharmacological interventions for the management of the symptoms associated with MPNs, given the limited evidence on the use of these modalities in these patient populations. 
